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Purpose: We evaluated mid-term results of a single-center consecutive series of endovascular stent-grafts implanted for
aortic aneurysm repair with transrenal fixation, to determine clinical outcome, aneurysm anatomy, renal artery patency,
and renal complications.
Methods: Modular stent-grafts were placed with transrenal fixation in 37 patients between November 1998 and July 2000.
Follow-up evaluation included clinical examination, laboratory evaluation of serum creatine concentration, computed
tomographic angiography, and renal duplex scanning.
Results: Thirty-seven patients underwent transrenal fixation of aortic stent-grafts as part of a Phase II US Food and Drug
Administration study. Two patients subsequently underwent follow-up at institutions closer to their homes, and thus
provided clinical information but no long-term renal or aneurysm morphologic data. There were no perioperative deaths.
Five patients died during follow-up, at a mean of 9 months, because of myocardial infarction in 4 patients and respiratory
failure in 1 patient. Thirty patients, ages 75 8 years, have been followed up for 28.5 7.2 months. Aneurysm diameter
at follow-up was 5.0  0.8 cm, compared with 5.7  0.8 cm preoperatively. In 5 patients, endoleak developed during
follow-up: 1 type I leak was treated with an aortic cuff, with temporary stabilization of the aneurysm and correction of
the endoleak; 2 type II endoleaks were treated with translumbar coil embolization, and 1 resolved spontaneously; and 1
type III endoleak was treated with a combination of coil embolization and stent-graft extension to cover a graft defect.
Preoperatively, serum creatinine concentration was normal in 23 patients, but increaesd persistently in 2 patients and was
abnormal in 7 patients. Postoperatively, creatine concentration increased in 4 patients to greater than 20% of baseline
level. Seventeen patients had no evidence of renal artery stenosis, compared with 13 patients with renal artery stenosis. Of
41 normal renal arteries, 90% remained unchanged, 1 became occluded, 3 demonstrated 60% stenosis. Nephrectomy was
necessary in 1 patient because of cancer. Of 19 abnormal renal arteries, progression of disease was noted in 3 arteries.
Conclusions: Transrenal fixation of aortic stent-grafts can be performed with acceptable mid-term outcome with respect
to mortality, need for follow-up intervention, and aneurysm exclusion with protection from rupture. Postprocedural
stenosis can develop in both normal and abnormal renal arteries. Rate of progression of disease was greater in patients
with preprocedural renal dysfunction compared with patients with normal renal arteries. This is merely an observation,
and may not be related to transrenal fixation. Long-term follow up is needed. (J Vasc Surg 2003;37:938-42.)
The unique design of grafts placed with transrenal
methods of fixation might enable broader application of
endoluminal stent-graft technology for treatment of infra-
renal aortic aneurysm. Currently several stent-graft manu-
facturers use this concept of enhanced proximal fixation,
with bare spring fixation across the level of the renal arter-
ies, sometimes crossing the mesenteric vessels. The long-
term consequences of this design are yet to be determined;
however, short-term data are favorable. We evaluated our
mid-term results in a consecutive series of patients in whom
grafts were placed with transrenal fixation, to determine
mortality, renal patency, and renal function.
METHODS
We prospectively studied all patients receiving aortic
stent- grafts with transrenal fixation who participated in a
series of Phase II US Food and Drug Administration
(FDA) investigations at our institution involving both elec-
tive and emergency use protocols. The emergency use
protocol reflected use in patients who were not suitable
candidates for conventional repair; however, this did not
imply use in the setting of ruptured or symptomatic aneu-
rysm. The study received full approval by our institutional
review board before initiation, and all patients gave in-
formed consent before participation.
All patients received Talent aortic stent-grafts (World
Medical/Medtronic/AVE, Santa Rosa, Calif) with transre-
nal fixation, with bare stent placement across the renal
arteries (Fig 1). Baseline demographic data were recorded
(Table I), as well as preoperative and postoperative data
regarding aneurysm anatomy and renal patency as observed
on computed tomography (CT) angiograms, renal duplex
scans (Figs 2 and 3), and angiograms, when available. In
addition, serum creatinine levels (normal, 0.7-1.5 mg/dL)
were evaluated preoperatively and at follow-up. Renal du-
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plex scanning was performed in our ICAVL-accredited
vascular laboratory. Duplex scanning criteria for renal ste-
nosis greater than 60% included renal-aortic flow velocity
ratio greater than 3.5. In addition, renal artery flow velocity
greater than 180 cm/s but without renal-aortic ratio 3.5
indicated less than 60% stenosis.
RESULTS
Between November 1998 and July 2000, 37 patients
received modular stent-grafts with transrenal fixation as
part of an ongoing Phase II FDA investigation. Thirty-one
patients were part of an elective protocol, and 6 patients
were enrolled in a high-risk emergency protocol. Two
patients were lost to intermediate follow-up, choosing to
undergo follow-up at institutions closer to their homes.
There was no operative or 30-day mortality (Table II).
Five patients died during follow-up. Two patients were in
the high-risk emergency group, for mortality at follow-up
of 33% (n  6) in this group. Both patients died of
myocardial infarction, at 4 and 15 months, respectively.
The other 3 patients were in the standard risk group, for
mortality at follow-up of 9.6% (n 31) in this group. Two
patients died of myocardial infarction, at 5 and 7 months,
respectively, and 1 patient died of respiratory insufficiency
and lung cancer at 12 months. Overall, mortality at fol-
low-up was 13.5%. Operative and 30-day mortality was 0%.
Mortality at 6 months was 5.4%, at 12 months was 10.8%,
and at 24 months was 13.5%. No visceral infarcts were
identified at follow-up on CT scans for any patients studied.
Thirty patients (26 men [87%]; mean age, 75  7.5
years [range, 58-87 years]) composed the mid-term fol-
low-up group and were evaluated for renal artery patency,
renal function, and aneurysm anatomy and exclusion. Aor-
tic neck length was 22  11.6 mm, and in 29% of patients
was less than 15 mm. Aortic neck diameter was 26.4 3.6
mm, and in 25% of patients was 30 mm or greater. Aortic
aneurysm diameter was 5.7  0.8 cm (range, 4.7-7.2 cm).
Mean aneurysm diameter at follow-up was 5.0 0.8 cm. In
19 patients (63%) aneurysm diameter decreased and in 10
patients aneurysm size remained stable.
In 1 patient aneurysm diameter increased. This was the
only patient in whom proximal type I endoleak developed,
at 6 months. Subsequently, a proximal aortic extension cuff
was placed, which initially stabilized the aneurysm. At most
recent follow-up (39 months), however, the aneurysm had
grown to 8 cm, without signs of endoleak on CT or duplex
Table I. Patient demographics (N  30)
Mean follow-up (mo) 28.5  7.2
Male-female ratio 26/4
Age (y)
Mean 75  7.5
Range 58–87
Aneurysm diameter (cm)
Mean 5.7  0.8
Range 4.7-7.2
Abnormal serum creatinine concentration* (mg/dL)










High risk/emergency use (20%)
No. of patients 6 (20%)
*Abnormal,  1.5 mg/dL.
Fig 1. Intraoperative angiogram demonstrates transrenal bare spring of a Talent aortic stent graft. Fabric begins at
radiopaque figure-of-eight markers.
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scans. At this point the patient has refused explantation of
the graft or further workup. The cause of the aneurysm
instability is uncertain, but it may be due to continued
degeneration of the proximal aorta or an undetected en-
doleak. It should be noted that the aorta immediately
proximal to the renal ostia is signficantly degenerated.
Three patients had persistent type II endoleak. In 1
patient the endoleak resolved spontaneously at 6 months,
and 2 patients underwent successful translumbar emboliza-
tion of the endoleak. One patient had a type III endoleak
due to graft failure in an iliac limb, with outflow to the
inferior mesenteric artery, as identified on an angiogram
that revealed a fabric defect at a seam. The inferior mesen-
teric artery was coil embolized, and another iliac limb was
placed to seal the defect.
Forty-one normal renal arteries were identified preop-
eratively. Thirty-six of these arteries (90%) remained un-
changed at follow-up. In 3 renal arteries stenosis pro-
gressed to more than 60%, on the basis of duplex scanning
criteria. One renal artery became occluded. One patient
underwent nephrectomy because of cancer. Overall rate of
stenosis progression was 10% (Table III).
There were 19 diseased renal arteries preoperatively.
Thirteen of these arteries (68%) remained unchanged. In 1
Fig 2. Transrenal fixation of aortic stent-graft with bilateral patent renal arteries.
Fig 3. Transrenal aortic stent-graft in patient with right renal artery occlusion.
Table II. Mortality at follow-up (N  37)
Mortality No. of patients Percent
Operative 0 0
30 days 0 0
6 months 2* 5.4
12 months 2† 10.8
24 months 1‡ 13.5
*Myocardial infarction.
†Myocardial infarction, 1; lung cancer, 1.
‡Myocardial infarction.
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patient mild stenosis progressed to severe stenosis (60%),
and in 2 patients mild stenosis progressed to moderate
stenosis (60%). In 3 patients, stenosis more than 60%
remained unchanged. Two of these patients underwent
angioplasty and stenting of the renal arteries, but subse-
quently significant acceleration in flow velocity was noted.
Rate of disease progression in patients with preexisting
renal artery stenosis was 16%. With the Fisher exact test,
used to compare degree of progression in patients with and
without preexisting disease, P  .044 was attained (Table
III).
Twenty-three patients had normal preoperative serum
creatinine concentration. However, at follow-up, abnormal
creatinine concentration was noted in 2 patients (8.7%). No
patient has required renal replacement therapy postopera-
tively.
Seven patients had abnormal preoperative serum creat-
inine concentration. In 4 of the 7 patients serum creatinne
concentration increased to more than 20% above baseline.
Despite this, no patient has required renal replacement
therapy.
DISCUSSION
Patients with preoperative renal dysfunction are at in-
creased risk for progressive postoperative dysfunction and
higher mortality.1-3 In addition, patients with postopera-
tive renal failure have higher mortality.4,5 The cause of
renal failure is often multifactorial and related to underlying
disease, eg, diabetes mellitus or, less commonly, renal arte-
rial occlusive disease. However, regardless of the cause,
certain risk factors have been established, including preop-
erative presence of renal disease, any occlusion of arterial
inflow to the kidneys during therapy, renal atheroembo-
lism, and contrast medium–related nephropathy. With the
varied mechanisms of renal failure or dysfunction, it is
unclear whether endoluminal or conventional therapy will
produce a more favorable outcome with respect to postop-
erative renal function. Several studies have evaluated the
short-term results of transrenally fixed aortic stent-grafts.
At mean follow-up of 6 months, Malina et al6 identified no
adverse effect on renal function with transrenally fixed
aortic stent-grafts in 18 patients who received Gianturco Z
stent–based grafts. Macierewicz et al7 and Marin et al8
compared grafts with transrenal fixation and with infrarenal
fixation, and found no adverse outcome with respect to
renal function. At our institution, early follow-up of our
series
9
also failed to reveal a significant adverse effect on
renal function or renal patency.
Longer follow-up (mean, 14 months) has been re-
ported by Kichikawa et al10. In their series, 18 patients
received transrenal custom-made Dacron stent-grafts sup-
ported with spiral Z stents. One patient demonstrated
transient elevation in renal function values, and postproce-
dural renal artery stenosis was identified 24 hours after graft
implantation. Bilateral renal artery stents were placed, with
resolution of renal insufficiency. Lobato et al11 reported 35
patients with mean follow-up of 11 months. Two patients
had renal artery stenosis, treated at endograft placement. In
1 patient progression to more than 60% stenosis was noted
postoperatively, which was successfully treated with renal
angioplasty and stenting at 4 months. Six patients had
stable renal artery stenosis at follow- up. These authors
concluded that in patients with normal renal arteries or
minimal disease, renal stenosis does not progress signifi-
cantly after endograft placement with transrenal fixation.
In the present series, we report 30 patients with mean
follow-up of 28.5 months, with acceptable mortality and
outcome. Our exclusion rate and incidence of secondary
intervention is comparable to that of previous reports. In
addition, renal function has been stable in patients with no
previous renal insufficiciency, based on preoperative stud-
ies. In 4 of 7 patients with renal insufficiency, renal function
worsened by more than 20%. Renal replacement therapy
was not used in either group. In some renal arteries with or
without previous evidence of stenosis there was subsequent
development of renal artery stenosis. The exact mechanism
of renal artery stenosis in patients who received aortic
stent-grafts with transrenal fixation is unclear. In the only
patient in whom renal artery occlusion developed, the
stent-graft fabric remained below the right renal artery
ostium on follow-up CT scans, suggesting that postopera-
tive morphologic changes did not result in graft migration.
However, atherosclerosis was present in the proximal seg-
ment of the artery. Either the atherosclerosis progressed,
resulting in occlusion or graft healing due to presence of
the stent-graft, or an open strut may have contributed to
the progression. Postprocedural progression of stenosis is a
relatively new finding as reported in the literature, and the
consequences will require further study.
Kramer et al12 reported a series of 99 patients, of whom
69 patients received stent-grafts with suprarenal fixation.
Sixteen renal infarctions were identified in the entire group,
but there was no significant difference between grafts with
infrarenal fixation (5.6%) versus suprarenal fixation (8.7%).
Izzedine et al13 reported their series of 39 patients with
transrenal stent grafts with a mean follow-up of 30 months.
In their patients, renal function remained stable, and they
conclude that renal function is not affected by transostial
placement of open stents for stent-graft fixation.
Although the results in our series are favorable and
confirm much of the short-term and mid-term results in the
literature with respect to clinical outcome, mortality, aneu-
Table III. Postoperative results at midterm follow-up (N
 30)
n %
Aneurysm size (cm) 5.0  0.8
Development of renal dysfunction 2 8.7
Normal preoperative group 2 8.7
Progression of renal dysfunction 4 57
Abnormal preoperative group
Progression of renal stenosis 4 10
Normal preoperative group 4 10
Abnormal preoperative group 3 16
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rysm exclusion, and postprocedural renal function, more
follow-up is necessary to determine the significance of renal
artery stenosis and transrenal fixation of aortic stent-grafts.
Comorbid factors have a major role in postoperative mor-
tality, as in open series. It remains uncertain whether pre-
operatively identified renal arterial lesions should be treated
before stent grafting, concomitantly with the stent-graft
procedure, after the procedure, or at all. Burks et al14
identify no significant morbidity with transvisceral place-
ment of aortic stent-grafts. Long-term follow-up, as re-
ported by Hertzer et al,15 who evaluated their experience
with open infrarenal aneurysm repair, is needed to truly test
the results of endoluminal repair. These authors report
30-day mortality of 1.2% and a low incidence (0.4%) of
graft-related complications. It will be many years before we
know whether endoluminal technology will rival this gold
standard.
REFERENCES
1. Joseph MG, McCollum PT, Lusby RJ. Abnormal pre-operative creati-
nine levels and renal failure following aortic aneurysm repair. Aust N Z
J Surg 1989;59:539-41.
2. Hallin A, Bergquist D, Holmberg L. Literature review of surgical
management of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg
2001;22:197-204.
3. Carpenter JP, Fairman RM, Barker CF, Golden MA, Velazquez OC,
Mitchell ME, et al. Endovascular AAA repair in patients with renal
insufficiency: strategies for reducing adverse renal events. Cardiovasc
Surg 2001;9:559-64.
4. Yasuhara H, Ishiguro T, Muto T. Factors affecting late survival after
elective abdominal aortic aneurysm repair. Br J Surg 1999;86:1047-52.
5. Luft FC, Hamburger RJ, Dyer JK, Szwed JJ, Kleit SA. Acute renal
failure following operation for aortic aneurysm. Surg Gynecol Obstet
1975;141:374-8.
6. Malina M, Brunkwall J, Ivancev K, Lindh M, Lindblad B, Risberg B.
Renal arteries covered by aortic stents: clinical experience from endo-
vascular grafting of aortic aneurysm. Eur J Vasc Endovasc Surg 1997;
14:109-13.
7. Macierewicz J, Walker SR, Vincent R, Wastie M, Elmarasy N, Hopkin-
son BR. Perioperative renal function following endovascular repair of
abdominal aortic aneurysms with suprarenal and infrarenal stents. Vas-
cular Surgical Society of Great Britain and Ireland. Br J Surg 1999;86:
696.
8. Marin ML, Parsons RE, Hollier LH, Mitty HA, Ahn J, Parsons RE, et
al. Impact of transrenal aortic endograft placement on endovascular
graft repair of abdominal aortic aneurysms. J Vasc Surg 1998;28:638-
46.
9. Bove PG, Long GW, Zelenock GW, Bendick PJ, Khoury MD, Burr
MO, et al. Transrenal fixation of aortic stent grafts for the treatment of
infrarenal aortic aneurysmal disease. J Vasc Surg 2000;32:697-702.
10. Kichikawa K, Uchida H, Maeda M, Ide K, Kubota Y, Sakaguchi S, et al.
Aortic stent-grafting with transrenal fixation: use of newly designed
spiral Z-stent endograft. J Endovasc Ther 2000;7:184-91.
11. Lobato AC, Quick RC, Vaughn PL, Rodriguez-Lopez J, Douglas M,
Diethrich EB. Transrenal fixation of aortic endografts: intermediate
follow-up of a single-center experience. J Endovasc Ther 2000;7:273-8.
12. Kramer SC, Seifarth H, Pamler R, Fleiter T, Buhring J, Sunder-Plass-
mann L, et al. Renal infarction following endovascular aortic aneurysm
repair: incidence and clinical consequences. J Endovasc Ther 2002;9:
98-102.
13. Izzedine H, Koskas F, Cluzel P, Mallet A, Maksud P, Deray G. Renal
function after aortic stent-grafting including coverage of renal arterial
ostia. Am J Kidney Dis 2002;39:730-6.
14. Burks JA Jr, Fairies PL, Gravereaux EC, Hollier LH, Marin ML.
Endovascular repair of abdominal aortic aneurysms: stent-graft fixation
across the visceral arteries. J Vasc Surg 2002;35:109-13.
15. Hertzer NR, Mascha EJ, Karafa MT, O’Hara PJ, Krajewski LP, Beven
EG. Open infrarenal abdominal aortic aneurysm repair: The Cleveland
Clinic experience from 1989 to 1998. J Vasc Surg 2002;35:1145-54.
Submitted Sep 16, 2002; accepted Nov 26, 2002.
DISCUSSION
Dr Joseph Giglia (Cincinnati, Ohio). I enjoyed your talk.
Have you added any antiplatelet agents secondary to the metal that
is over the origin of the renal arteries? I have been concerned in a
couple of cases where I have covered the left subclavian or the
celiac axis with custom-made grafts and I have kept those people
on long-term antiplatelet agents.
Dr Bove. We have not consciously made an effort to do that.
Certainly, just because of the other comorbid factors that a lot of
the patients have, they are on aspirin or Plavix, but that would be
an interesting thing to look at, and it would be worthwhile to go
back and review.
Dr Christopher K. Zarins (Stanford, Calif). That was a great
presentation. I have two questions. The first is, you described the
technique of opening the graft superiorly and then pulling it down
to cover the renal, and my question is, Do you think that technique
might play a role in that one patient whose occluded renal artery
may have been injured in the process of pulling down the bare
spring over the renal orifice? My second question is, Do you have
any data to address this conclusion of potential added benefit of
treating anatomically difficult aortic necks? Were your necks ana-
tomically difficult? Do you think that this suprarenal fixation has
actually allowed you to treat different necks than you otherwise
might have, and do you have any data on that issue?
Dr Bove. It definitely is possible that the technique of pulling
the graft down may have created an atheroembolic event or some-
thing that had damaged the ostium of the renal artery. It was not
evident during that specific patient’s case, and the renal artery was
widely patent post the procedure, but that patient had severe
vasculopathy. Two weeks or a month prior to his implantation he
actually was found to have a critical carotid stenosis, and we had to
take care of that first. Clearly, it is possible that some mechanical
event occurred. That is the technique that we typically utilize,
deploying it slightly above the renals and drawing it down, and
have not experienced significant atheroembolic complications ei-
ther to the viscera or to the lower extremities, but that definitely
could have been the mechanism.
Specifically, with the data that is in this presentation, a third of
our patients, or 29%, had necks that were less than 15 mm in
length, so I think that a significant portion would be shorter necks.
If you go by the instructions for use with the various grafts, that
would take them out of the FDA-approved grafts, although many
of us have treated shorter necks with the FDA-approved grafts. The
other thing is, and this is specific to the design of the Talent grafts,
it allows you to treat larger necks that would not be treatable by
other devices. But it would be interesting to go back and look at
degrees of angulation and see if that played a role.
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